MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 2 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.35 (290.19% upside)

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetActions
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
3/24/2016Q4($0.32)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.33)($0.50)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.43)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.57)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.33)($0.49)$375.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.44)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.47)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Eleven Biotherapeutics (NASDAQ:EBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
DateHeadline
06/23/16 02:41 PMEleven Biotherapeutics (EBIO) to Eliminate 14 Positions, 70% of Workforce - StreetInsider.com
06/22/16 03:28 PMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Material Impairme -
06/20/16 01:22 PMETF’s with exposure to Eleven Biotherapeutics, Inc. : June 20, 2016 -
06/19/16 03:30 PMThis Weeks Broker Views For Eleven Biotherapeutics Inc (EBIO) - Fiscal Standard
06/18/16 08:17 AMEleven Biotherapeutics Inc. (EBIO) Jumps 15.25% on June 16 - Equities.com
06/16/16 08:59 PMEleven Biotherapeutics Inc(NASDAQ:EBIO): That’s How Our Premium Members Made A Quick 140% Profit
06/16/16 03:45 PMComprehensive Report on: Cerner Corporation (NASDAQ:CERN), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle
06/15/16 03:48 PMShire PLC (ADR) (NASDAQ:SHPG) & Eleven Biotherapeutics (NASDAQ:EBIO) Healthcare Trend Analysis Report - Wall Street 24
06/15/16 03:48 PMEleven Biotherapeutics (EBIO) Showing Signs Of A Dead Cat Bounce Today - TheStreet.com
06/15/16 08:30 AMNotable Analysts Recommendation to Monitor: GlaxoSmithKline PLC (NYSE:GSK) , Eleven Biotherapeutics, Inc ... - Street Updates
06/15/16 08:30 AMComplete Analysis of: Juniper Networks, Inc. (NYSE:JNPR), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle
06/14/16 03:38 PMTeva Pharmaceutical Industries (NYSE:TEVA) & Eleven Biotherapeutics (NASDAQ:EBIO) Hot Stock's Alert - Wall Street 24
06/14/16 03:38 PMEarnings Analysis to see: Ford Motor Co. (NYSE:F), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle
06/14/16 08:36 AMNoteworthy Analysts Suggestions: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Galena Biopharma, Inc. (NASDAQ ... - Street Updates
06/14/16 08:36 AMEleven Biotherapeutics Inc. (EBIO) Jumps 27.81% on June 13 - Equities.com
06/13/16 03:33 PMPrice Target by Brokers: Sunstone Hotel Investors Inc. (NYSE:SHO), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Beacon Chronicle
06/13/16 03:33 PMEleven Biotherapeutics Inc (EBIO) Soars on Roche Holding Ltd. (ADR) Deal - Investorplace.com
06/13/16 08:25 AMSummary of Analysts Rating: Celgene Corporation (NASDAQ:CELG) , Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Street Updates
06/13/16 08:25 AMHC Stocks Analysis: Hologic, Inc. (NASDAQ:HOLX), Eleven Biotherapeutics Inc (NASDAQ:EBIO) - share market updates (press release)
06/13/16 08:25 AMEleven Biotherapeutics (EBIO) Submits IND for Phase 1 Clinical Trial of EBI-031 - StreetInsider.com
06/13/16 07:40 AMWhy Eleven Biotherapeutics Is Making a Run -
06/13/16 07:09 AMEleven Biotherapeutics Announces Signing of Exclusive License Agreement - [at noodls] - a8980e68-64ee-416e-a666-97152c2f0d90.pdf June 13, 2016 License to Roche Covers IL-6 Antagonist Antibody Technology, Including EBI-031 IND Submission for EBI-031 Announced Today CAMBRIDGE, Mass.--(BUSINESS ...
06/13/16 06:55 AMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Regulation FD Disclosure, Financial Statements and Exh -
06/13/16 06:49 AMEleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases - [at noodls] - 5915a4c9-6dab-4e52-b3c8-2c93eaf5df62.pdf June 13, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics ...
06/11/16 08:25 AMEleven Biotherapeutics Inc. (EBIO) Drops 8.2% on June 09 - Equities.com
06/10/16 03:15 PMELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 02:41 PMNotable Earnings Analysis: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Chico's FAS Inc. (NYSE:CHS) - Beacon Chronicle
06/08/16 02:41 PMMost Recent Update on Price Moves: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Kite Pharma, Inc. (NASDAQ:KITE) - Street Updates
06/08/16 08:41 AMAnalyst's Valuable Buzzers: Pfizer, Inc. (NYSE:PFE) , Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Street Updates
06/07/16 03:50 PMPrice Target Highlight: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - News Oracle
06/07/16 09:41 AMHC Stocks Overview: CVS Health Corp (NYSE:CVS), Eleven Biotherapeutics Inc (NASDAQ:EBIO) - share market updates (press release)
06/07/16 09:41 AMNotable Earnings Analysis: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Vodafone Group Plc (NASDAQ:VOD) - Beacon Chronicle
06/06/16 09:07 PMOracle Corporation (NYSE:ORCL) & Eleven Biotherapeutics (NASDAQ:EBIO) Movers to Watch - Wall Street 24
06/06/16 09:07 PMEarnings Analysis to Watch: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Regions Financial Corporation (NYSE:RF) - Beacon Chronicle
06/06/16 04:29 PMETF’s with exposure to Eleven Biotherapeutics, Inc. : June 6, 2016 -
06/06/16 03:35 PMEye Catching Stock for investors: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - News Oracle
06/06/16 03:35 PMEleven Biotherapeutics Inc (NASDAQ:EBIO) Defies The Bears - Insider Financial
06/06/16 07:04 AMHC Stocks Indication: Pfizer Inc. (NYSE:PFE), Eleven Biotherapeutics Inc (NASDAQ:EBIO) - share market updates (press release)
06/04/16 03:45 PMEleven Biotherapeutics, Inc. (NASDAQ:EBIO): Updated Analyst Ratings - iStreetWire
06/03/16 09:54 PMEleven Biotherapeutics Inc. (EBIO) Jumps 20.79% on June 03 - Equities.com
06/03/16 03:57 PMEarnings Overview of the Stocks: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Encana Corporation (NYSE:ECA) - Beacon Chronicle
06/03/16 03:57 PMActive Movers - International Business Machines Corp., (NYSE:IBM), Eleven Biotherapeutics, (NASDAQ:EBIO) - Wall Street 24
06/03/16 11:40 AMWhy Weatherford International, Freeport-McMoRan and Three Others Stocks are Gaining Ground Today? -
06/03/16 10:03 AMEleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 -
06/03/16 09:13 AMEleven Biotherapeutics Inc. (EBIO) Jumps 34.85% on June 02 - Equities.com
06/03/16 08:17 AMThese Stocks Are Making Big Moves -
06/02/16 03:52 PMWorthy Stocks in the Spotlight: Eleven Biotherapeutics Inc (NASDAQ:EBIO), Peregrine Pharmaceuticals (NASDAQ ... - The Point Review - The Point ReviewWorthy Stocks in the Spotlight: Eleven Biotherapeutics Inc (NASDAQ:EBIO), Peregrine Pharmaceuticals (NASDAQ ...The Point ReviewShares of Eleven Biotherapeutics Inc (NASDAQ:EBIO) flew 34.85% to $1.78 at 11:57 AM EDT. The stock attained the volume of 10.97 Million shares recently versus average trading volume of 3.66 Million shares. If we take a look on its volatility, 13.96 ...and more »
06/02/16 03:08 PM6 Biotechs Seriously on the Move -
06/02/16 08:22 AMEleven Biotherapeutics Incorporated (NASDAQ:EBIO) Sellers Increased By 11.48% Their Shorts - HNN - Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) Sellers Increased By 11.48% Their ShortsHNNThe short interest to Eleven Biotherapeutics Incorporated's float is 19.04%. The stock increased 6.45% or $0.08 during the last trading session, hitting $1.32. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has declined 49.81% since October 26, 2015 and is ...and more »
06/02/16 08:22 AMEleven Biotherapeutics Inc (EBIO) Drops 6.06% on May 31 - Equities.com - iStreetWireEleven Biotherapeutics Inc (EBIO) Drops 6.06% on May 31Equities.comEleven Biotherapeutics Inc (EBIO) was one of the Russell 2000's biggest losers for Tuesday May 31 as the stock slid 6.06% to $1.24, a loss of $-0.08 per share. Starting at an opening price of $1.32 a share, the stock traded between $1.21 and $1.36 over ...Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Earns Consensus Hold RatingiStreetWireall 2 news articles »
About Eleven Biotherapeutics

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Company's lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EBIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.29
  • 50 Day Moving Average: $1.61
  • 200 Day Moving Average: $1.19
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $32.94M
  • Current Quarter EPS Consensus Estimate: $-1.75 EPS
Additional Links:
Eleven Biotherapeutics (NASDAQ:EBIO) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha